Path to developing cost effective solutions for therapeutic monoclonal antibodies-Amita Goel-04/15/2014 - 8:30am

Event Information
Event Topic: 
Path to developing cost effective solutions for therapeutic monoclonal antibodies
Event Date: 
04/15/2014 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
Speaker Information
Event Speaker: 
Amita Goel
Event Speaker Title: 
Founder and CEO
Event Speaker Company: 
Celltheon Corporation
Event Speaker Bio: 

Ms. Amita Goel is the founder and CEO of Celltheon Corporation that she started in early 2012, Celltheon is a contract research company with a focus on developing cell lines and manufacturing process for biologics and generating material for preclinical studies, and diagnostic applications. Celltheon’s
SMART Bioprocessing Technology ™ has enabled increase in titers from 5-25 fold and decreased cost of production several fold. Celltheon has developed processes for large Global Pharma’s to mid-size biotech companies and Government institutions such as the CDC.

Ms. Goel holds a BS from Texas Tech University and a Masters from San Jose State in Microbiology and has authored several publications and won awards for her distinguished achievements at various institutions. She has over 25 years of industry experience as a scientist with increasing management responsibilities at companies like Hybritech, Purdue Pharma, Elan Pharmaceuticals, Arresto Biosciences and Gilead where she was involved in the development of mammalian cell lines and manufacturing processes for a number of bio therapeutics for preclinical and clinical programs like Multiple Sclerosis,

Alzheimer’s disease, Parkinson’s disease, Oncology, and Immuno Pulmonary Fibrosis (IPF).

Event Details
Event Details: 

Biotherapeutic drug development continues to be a rapidly growing field and a large number of these drugs, like monoclonal antibodies have been approved for treatment of patients. It is estimated that hundreds of new monoclonal antibodies could enter preclinical and clinical development each year. There is still considerable unmet medical need in the three main areas of study - cancer, immunological and infectious diseases, and these emerging agents could provide valuable new treatment options. Also with the growth in Biosimilar, the global competition for biologics manufacturing has put immense pressure to shorten time to market.

Growth and state of the art in the biotechnology industry promises to shrink developmental workflows by substituting time-intensive steps with rapid ones, thus shortening product and process development timelines.

Join us for a discussion on these technologies that have helped reduce the time lines.